Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

A startup seeking to replace animal testing with a sophisticated high-tech platform has raised $40 million to develop ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, ...

Researchers discovered that two neighboring genes, old and zao, regulate antiviral responses and symptom expression in the ...

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, ...